Peter Blume-Jensen

CIK: 0001950499

Transaction Breakdown

Open Market Buys (P)1 (3.0%)

High conviction signal

Open Market Sales (S)3 (9.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (24.2%)

Compensation grants

Other (G, F, J, C, D, …)21 (63.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRV

Acrivon Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (33 total)

ACRV
Acrivon Therapeutics, Inc.
Aug 25, 2026
Sale(S)
Direct
14K shares at avg. $2.21$31K
ACRV
Acrivon Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Direct
1.2K shares at avg. $2.01$2K
ACRV
Acrivon Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Indirect
484 shares at avg. $2.01$972.84
ACRV
Acrivon Therapeutics, Inc.
May 21, 2026
Tax Payment(F)
Direct
13.7K shares at avg. $1.79$25K
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Direct
180.1K shares-
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Indirect
72.7K shares-
ACRV
Acrivon Therapeutics, Inc.
May 14, 2026
Tax Payment(F)
Direct
1.3K shares at avg. $1.92$2K
ACRV
Acrivon Therapeutics, Inc.
May 14, 2026
Tax Payment(F)
Indirect
490 shares at avg. $1.92$940.8
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
417.2K shares-
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2026
Award(A)
Stock Option (Right to Buy)
Indirect
185.5K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 21, 2026
Tax Payment(F)
Direct
14.3K shares at avg. $1.53$22K
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Direct
1.3K shares at avg. $1.63$2K
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Indirect
579 shares at avg. $1.63$943.77
ACRV
Acrivon Therapeutics, Inc.
Jan 14, 2026
Purchase(P)
Direct
49K shares at avg. $1.68$82K
ACRV
Acrivon Therapeutics, Inc.
Nov 21, 2025
Tax Payment(F)
Direct
19.9K shares at avg. $2.30$46K
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2025
Tax Payment(F)
Direct
59.8K shares at avg. $2.24$134K
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2025
Tax Payment(F)
Indirect
490 shares at avg. $2.24$1K
ACRV
Acrivon Therapeutics, Inc.
Aug 21, 2025
Tax Payment(F)
Direct
19.9K shares at avg. $1.32$26K
ACRV
Acrivon Therapeutics, Inc.
Aug 14, 2025
Tax Payment(F)
Indirect
490 shares at avg. $1.39$681.1
ACRV
Acrivon Therapeutics, Inc.
Aug 14, 2025
Tax Payment(F)
Direct
59.8K shares at avg. $1.39$83K
ACRV
Acrivon Therapeutics, Inc.
May 21, 2025
Tax Payment(F)
Direct
19.9K shares at avg. $1.15$23K
ACRV
Acrivon Therapeutics, Inc.
May 14, 2025
Tax Payment(F)
Direct
59.8K shares at avg. $1.14$68K
ACRV
Acrivon Therapeutics, Inc.
May 14, 2025
Tax Payment(F)
Indirect
491 shares at avg. $1.14$559.74
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2025
Award(A)
Stock Option (Right to Buy)
Indirect
140.5K shares-
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
390.4K shares-

		Type	Shares	Price		Ownership
Aug 25, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	14,036	$2.21	$30,969	Direct
Aug 18, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	1,229	$2.01	$2,470	Direct
Aug 18, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	484	$2.01	$973	Indirect
May 21, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	13,729	$1.79	$24,575	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	180,095	-	$0	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	72,706	-	$0	Indirect
May 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	1,253	$1.92	$2,406	Direct
May 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	490	$1.92	$941	Indirect
Mar 1, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	417,210	-	-	Direct
Mar 1, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	185,495	-	-	Indirect
Feb 21, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	14,265	$1.53	$21,825	Direct
Feb 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	1,302	$1.63	$2,122	Direct
Feb 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	579	$1.63	$944	Indirect
Jan 14, 2026	ACRV Acrivon Therapeutics, Inc.	Purchase(P)	49,000	$1.68	$82,124	Direct
Nov 21, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	19,904	$2.30	$45,779	Direct
Nov 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	59,765	$2.24	$133,874	Direct
Nov 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	490	$2.24	$1,098	Indirect
Aug 21, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	19,905	$1.32	$26,275	Direct
Aug 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	490	$1.39	$681	Indirect
Aug 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	59,766	$1.39	$83,075	Direct
May 21, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	19,904	$1.15	$22,890	Direct
May 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	59,766	$1.14	$68,133	Direct
May 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	491	$1.14	$560	Indirect
Mar 1, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	140,540	-	-	Indirect
Mar 1, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	390,390	-	-	Direct

1-25 of 33 transactions

About Blume-Jensen Peter

Blume-Jensen Peter (SEC CIK 0001950499) files insider reports with the SEC as President and CEO of Acrivon Therapeutics, Inc. (ACRV).

Signal8 holds 21 ownership filings by Blume-Jensen Peter, all Form 4s, filed between Nov 18, 2024 and Aug 27, 2026. Those filings report 33 transactions, from Mar 1, 2024 to Aug 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Blume-Jensen Peter's filings is in WATERTOWN, MA.

Recent filings by Blume-Jensen Peter

Aug 25, 2026: Open-market sale of ACRV shares (Form 4, code S).
Aug 18, 2026: Open-market sales of ACRV shares (2 lines, Form 4, code S).
May 21, 2026: Tax withholding of ACRV shares (Form 4, code F).
May 18, 2026: Grants or awards of ACRV shares (2 lines, Form 4, code A).
May 14, 2026: Tax withholdings of ACRV shares (2 lines, Form 4, code F).

Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)

Miller Mary, Chief Legal Officer
Levin Michaela, Chief Business Officer
Peterson Katharine, Chief Accounting Officer
Gamelin Erick, Chief Development Officer
Devroe Eric, Chief Operating Officer
Levy Adam D., Chief Financial Officer

How to read Form 4 transaction codes